Neovacs Raises 250,000 Euros through OCEANE-BSA to Fund mRNA Programs
Neovacs announces a fundraising of 250,000 euros through the issuance of OCEANE-BSA subscribed by Hanover Square Investments. This operation is part of the scheduled financing calendar for 2026 and aims to fund activities in the fields of asthma, allergies, and programs focused on mRNA strategies.
Utilization of the Funds
The net proceeds from this raise, amounting to 245,000 euros after expenses, will be used to fund activities in the fields of asthma and allergies, as well as programs focused on mRNA strategies. This operation complements the financing schedule planned for 2026, which was announced on March 24, 2026.
Details of the OCEANE-BSA Issue
The issuance of OCEANE-BSA resulted in the creation of 25 million share subscription warrants. Prior to this draw, the OCEANE-BSA issuances under the contract with Hanover Square Investments had already raised 1,250,000 euros. The total issuances to date could lead to the creation of 349,613,716 new shares based on the last quoted price. The role of the initial subscriber is to ensure a gradual fundraising for the company by selling the securities progressively on the market, without the intention to remain a long-term shareholder.
